

Childhood Liver Disease Research and Education Network (ChiLDREN)

A RANDOMIZED, DOUBLE-BLINDED, PLACEBO- CONTROLLED TRIAL OF CORTICOSTEROID THERAPY FOLLOWING PORTOENTEROSTOMY IN INFANTS WITH BILIARY ATRESIA

Manual of Operations (MOO)

1 April 2007 (Version 1)

LAST EDITED on 01 September 2010

CHAPTER 0. TABLE OF CONTENTS

CHAPTER 1. OVERVIEW

1.1 Summary of Study

CHAPTER 2. SCREENING AND RECRUITMENT

2.1 Population

2.2 Screening/Recruitment Plan

2.3 Eligibility/Exclusion Criteria

2.3.1 Inclusion Criteria

2.3.2 Exclusion Criteria

2.4 Exceptions to the Inclusion/Exclusion Criteria

2.4.1 Details about Certain Eligibility Criteria

2.5 Screening/Enrollment Logs

CHAPTER 3. INFORMED CONSENT

3.1 Informed Consent Document

3.2 Obtaining Informed Consent

3.3 Re-Consent

3.4 Health Insurance Portability & Accountability Act (HIPAA) Compliance

3.5 Non-English-Speaking Subjects

3.5.1 Other issues related to translators

CHAPTER 4. STUDY VISIT DETAILS

4.1 Visit Descriptions

4.1.1 Types of Visits

4.2 Case Report Form (CRF) Description and Instructions

4.2.1 Baseline

4.2.1.1 Form S11 Eligibility (web-entry)

4.2.1.2 Randomization Process at Baseline

4.2.1.3 Drug Kit Assignment at Baseline

4.2.1.4 Administration of Study Drug or Placebo at Baseline

4.2.1.5 Adjunct Medications and Treatment at Baseline (ursodiol, vitamin K, AquADEK™, TMP-SMZ (Bactrim), Ranitidine (Zantac®))

4.2.1.6 Discharge to Home Information

4.2.2 2-Week Follow-Up Visit

4.2.3 1-Month Follow-Up Visit

4.2.4 2-Month Follow-Up Visit

4.2.5 3-Month Follow-Up Visit

4.2.6 6-Month Follow-Up Visit

4.2.7 12-Month Follow-Up Visit

4.2.8 18-Month Follow-Up Visit

4.2.9 24-Month Follow-Up Visit

4.2.10 Study-Specific Procedures for Subjects Undergoing Liver Transplantation Prior to 2 Years of Age

4.2.11 Important CRFs Used Throughout the START Study

4.3 Pharmacy Dispensing of Study Medications

4.3.1 Dispensing Steroid/Placebo

4.3.2 Dispensing Other Study Medications

4.3.3 Patient Drug Accountability

4.4 Dose Reductions

4.5 Tapering

4.5.1 Blinded Taper

4.5.2 Unblinded Taper

4.5.3 Restarting Study Drug Related to Complication

4.6 Steroid Pulses

4.7 Tracking Study Medication Use

4.8 Administration Instructions for Study Medications

- 4.8.1 Administration Instructions for Steroid/Placebo
 - 4.8.1.1 Schedule of Dosing
 - 4.8.1.2 Guidelines for Giving a Second Dose if Child Spits Ups/Vomits First Dose
 - 4.8.1.3 Two-Week Drug Adjustment
 - 4.8.1.4 Instructions for the Family Administering Steroid/Placebo
- 4.8.2 Administration Instructions for AquADEK™ and Vitamin K (Mephyton®)
 - 4.8.2.1 Schedule of Dosing
 - 4.8.2.2 Guidelines for Giving a Second Dose if Child Spits Ups/Vomits First Dose
 - 4.8.2.3 Accountability for Vitamins
 - 4.8.2.4 Instructions for the Family Administering AquADEK™ and Vitamin K
- 4.8.3 Administration Instructions for Ursodeoxycholic Acid (Urso 250® or Actigall®)
 - 4.8.3.1 Schedule of Dosing
 - 4.8.3.2 Instructions for the Family Administering Ursodeoxycholic Acid (Urso 250® or Actigall®)
- 4.8.4 Administration Instructions for Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Bactrim)
 - 4.8.4.1 Schedule of Dosing
 - 4.8.4.2 Dose Adjustment
 - 4.8.4.3 Instructions for the Family Administering TMP-SMZ (Bactrim)
- 4.8.5 Administration Instructions for Ranitidine (Zantac®)
 - 4.8.5.1 Schedule of Dosing
 - 4.8.5.2 Instructions for the Family Administering Ranitidine (Zantac®)
- 4.8.6 Administration Instructions for Ranitidine (Zantac®)
 - 4.8.6.1 Schedule of Dosing

4.9 Transferring START Subjects from One Clinical Site to Another

- 4.9.1 Subjects Taking Steroid/Placebo
 - 4.9.1.1 Tasks: 'From'-Site (study site from which subject is transferring from)
 - 4.9.1.2 Tasks: 'To'-Site (study site to where subject is transferring to)
 - 4.9.1.3 Tasks: Central Pharmacy
- 4.9.2 Subjects Done Taking Steroid/Placebo
 - 4.9.2.1 Tasks: 'From'-Site (study site from which subject is transferring from)
 - 4.9.2.2 Tasks: 'To'-Site (study site to where subject is transferring to)

CHAPTER 5. SPECIMEN COLLECTION

5.1 Vitamin Levels Assessment

- 5.1.1 Schedule
- 5.1.2 Testing
- 5.1.3 Sample Size Requirements

- 5.1.4 Specimen Labeling
- 5.1.5 Specimen Collection and Processing
- 5.1.6 Shipping Procedures
- 5.1.7 Results

5.2 Whole Blood for Genetics

5.3 Antibody Titers

CHAPTER 6 ADVERSE EVENT (AE) / SERIOUS ADVERSE EVENT (SAE) / REGULATORY BODIES REPORTING

6.1 Definitions

6.2 Procedures for Reporting Serious Adverse Events (SAEs)

- 6.2.1 Personnel Involved with SAEs
- 6.2.2 Contacts for Reporting of SAEs
- 6.2.3 Automated SAE Notification System
- 6.2.4 Reporting to the Food and Drug Administration (FDA)
- 6.2.5 Reporting to the Local Institutional Review Board (IRB)
- 6.2.6 Forms Completion for SAEs
 - 6.2.6.1 Form 45 Adverse Event (web-entry)
 - 6.2.6.2 Form 45A SAE Supplemental Data

6.3 Other Reporting Scenarios

- 6.3.1 Unexpected SAEs
- 6.3.2 Unexpected, Non-Serious AEs
- 6.3.3 Expected AEs During Follow-Up Visits
- 6.3.4 SAEs After Transplant for START
- 6.3.5 Reporting Summary

6.4 Monitoring and Management of Specific Expected AEs

- 6.4.1 Hypertension
 - 6.4.1.1 Measuring Blood Pressure (BP)
 - 6.4.1.2 Hypertension Prior to the First Dose of Steroid/Placebo
 - 6.4.1.3 Hypertension at Follow-Up Visits
 - 6.4.1.4 Summary of Hypertension Action Plan
 - 6.4.1.5 Treatment Choices
- 6.4.2 Hyperglycemia
 - 6.4.2.1 Measuring Hyperglycemia
 - 6.4.2.2 Hyperglycemia Decision Tree
 - 6.4.2.3 Summary of Hyperglycemia Action Plan
- 6.4.3 Hypokalemia
 - 6.4.3.1 Hypokalemia Decision Tree
 - 6.4.3.2 Summary of Hypokalemia Action Plan
- 6.4.4 Impaired Wound Healing
 - 6.4.4.1 Impaired Wound Healing Decision Tree

- 6.4.4.2 Summary of Impaired Wound Healing Action Plan
- 6.4.5 Gastrointestinal (GI) Bleeding
 - 6.4.5.1 GI Bleeding Decision Tree
 - 6.4.5.2 Summary of GI Bleeding Action Plan
- 6.4.6 Pancreatitis
 - 6.4.6.1 Pancreatitis Decision Tree
 - 6.4.6.2 Summary of Pancreatitis Action Plan
- 6.4.7 Irritability
 - 6.4.7.1 Irritability Decision Tree
- 6.4.8 Hypersensitivity Reaction to Trimethoprim-Sulfamethoxazole (TMP-SMZ) (Bactrim)
- 6.4.9 Cataracts
- 6.4.10 Vitamin Toxicity
- 6.4.11 Any Infectious Acute Illness
- 6.4.12 Development of Septicemia and Opportunistic Infections
- 6.4.13 Adrenal Insufficiency
 - 6.4.13.1 Adrenal Insufficiency While the Subject is Receiving Study Drug/Placebo Prior to the First Dose of Steroid/Placebo
 - 6.4.13.2 Adrenal Insufficiency Following Taper
- 6.4.14 Failure to Thrive or Poor Weight Gain
- 6.4.15 Life Threatening Events
 - 6.4.15.1 Breaking the Study Blind

CHAPTER 7 PREGESTIMIL

- 7.1 Schedule of Supplementation**
- 7.2 Receiving/Shipment Schedule**
- 7.3 Dispensing**
- 7.4 Sterility**
- 7.5 Returning Formula to Mead Johnson**
- 7.6 Damaged or Expired Formula**
- 7.7 Contacts**

Appendix A Pregestimil Log